Genetic differences among HIV-1 variants can influence the virus biological properties,
susceptibility to existing and candidate antiretroviral drugs, and evolution of antiretroviral …

Background. Because antiretrovirals are becoming increasingly available in developing
countries, we reviewed the findings of studies that have documented highly active …

Background. It has been proposed that subtype-related human immunodeficiency virus type
1 (HIV-1) variability may influence virologic and immunologic responses to highly active …

Background Antiretroviral therapy (ART) effectively decreases tuberculosis (TB) incidence
long-term, but is associated with high TB incidence rates in the first 6 months. We sought to …

ABSTRACT Kaposi's sarcoma (KS), caused by KS-associated herpesvirus (KSHV), is the
most common cancer among HIV-infected patients in Malawi and in the United States today …

Ninety percent of HIV-1-infected people worldwide harbour non-subtype B variants of HIV-1.
Yet knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited …

HIV and tuberculosis (TB) are leading global causes of mortality and morbidity, and yet
effective treatment exists for both conditions. Rifamycin-based anti-tuberculosis therapy can …

BACKGROUND: The safety and efficacy of nevirapine (NVP) and efavirenz (EFV) based
highly active antiretroviral treatment (ART) with concurrent anti-tuberculosis treatment in sub …

Late presentation remains a major concern despite the dramatically improved prognosis
realized by ART. We define a first presentation for HIV care during the course of HIV …

Objective: To describe the safety and efficacy of highly active antiretroviral therapy (HAART)
in pregnant women treated in an integrated antiretroviral antenatal clinic (ANC ARV) …